Current prognostic models for myelodysplastic syndromes (MDS) do not allow the identification of patients with lower risk disease and poor prognosis that may benefit from early therapeutic intervention. We evaluated the characteristics of 856 patients with low or intermediate-1 disease by the International Prognostic Scoring System. Mean follow-up was 19.6 months (range 1-262). Of these patients, 87 (10%) transformed to acute myelogenous leukemia, and 429 (50%) had died. By multivariate analysis, characteristics associated with worse survival (Po0.01) were low platelets, anemia, older age, higher percent of marrow blasts and poor-risk cytogenetics. Although not included in the model, higher ferritin (P ¼ 0.007) and b2-microglobulin (Po0.001) levels were associated with worse prognosis. This allowed the development of a scoring system in which patients could be grouped in three categories: category 1 (n ¼ 182, 21%) with a median survival of 80.3 months (95% CI 68-NA); category 2 (n ¼ 408, 48%) with a median survival of 26.6 months (95% CI 22-32) and category 3 (n ¼ 265, 31%) with a median survival of 14.2 months (95% CI 13-18). In summary, this analysis indicates that it is possible to identify patients with lower risk MDS and poor prognosis who may benefit from early intervention.
Introduction
Myelodysplastic syndrome (MDS) includes a group of hematopoietic disorders characterized by peripheral cytopenias and an increased risk of transformation to acute myelogenous leukemia (AML). Classifications of MDS include the French-AmericanBritish (FAB), 1 the World Health Organization (WHO) 2 and the International Prognostic Scoring System (IPSS). 3 Each of these classifications has limitations. The FAB and WHO classifications do not include age or cytogenetics, and therefore have limited value in assessing patient-specific risk. The IPSS is more comprehensive and includes percentage of blasts, cytogenetic alterations and number of cytopenias. It allows to estimate the overall survival and risk of AML transformation, based on the age of the patient. Because most patients analyzed in the original IPSS study had not received therapy, IPSS is currently the best tool to predict the natural history of untreated MDS. Despite its advantages, IPSS has several limitations, the most important of which is that it does not identify patients with lower risk disease (IPSS low or intermediate-1 risk) and poor prognosis who may be candidates for early therapeutic intervention, such as participation in clinical trials. This information is particularly relevant now that three new therapies have been recently approved for the treatment of MDS [4] [5] [6] and because patients with lower risk disease account for close to two-thirds of patients with MDS. Patients with lower risk disease and poor prognosis could benefit from early therapeutic interventions instead of the 'watch and wait' approach currently followed by many clinicians. The development of a new classification for patients with lower risk MDS may have a significant impact on clinical trial development and on the assessment of the comparative benefit of different therapies in MDS. In this study, we analyzed the characteristics of a large cohort of patients with lower risk MDS, and developed a prognostic model that segregates patients into three different risk groups. This data serves as a platform to develop clinical trials or interventions specifically targeting patients with lower risk MDS. 
Materials and methods

Patients
Statistical methods
Survival was calculated from the day of referral until death from any cause. Observations were censored for patients last known to be alive. Observations of AML progression-free survival were censored at the date of last contact for patients with no report of progression who were last known to be alive. Distributions of survival and progression-free-survival (PFS) were estimated by the method of Kaplan and Meier, and compared between subgroups using the log rank test. 7 Cox proportional hazards regression model 8 was used to assess the ability of patient characteristics to predict survival and PFS, with goodness-of-fit assessed by Martingale residual plots, the Grambsch-Therneau test, 9 Schoenfeld residual plots, and the likelihood ratio (LR) test. Interactions between variables selected in the final model were also checked. The following characteristics were evaluated: age, gender, performance status, hemoglobin, platelet count, white cell count (WBC), morphology (MDS versus chronic myelomonocytic leukemia), number of cytopenias, hepatomegaly, karyotype, percent of marrow blasts, creatinine, albumin, infection at presentation, history of prior malignancy and duration of antecedent hematological disorder. Since patients were referred to our institution from 1976 to 2005, the year of referral was also studied to consider changes in clinical practice and supportive care. Two other characteristics, ferritin and b2-microglobulin were also studied. Because their values were known only for a subset of patients, these were not included in the multivariate analysis.
Results
Patients
The characteristics of 856 patients with low-and intermediate-1-risk MDS are shown in Table 1 . Their IPSS score was calculated based on their initial presentation to our institution. Of these patients, 250 (29%) had low-risk disease and 606 (71%) had intermediate-1 risk. The median follow-up was 11.7 months (mean follow-up 19.6 months; range 1-262). At the time of last follow-up, 429 (50%) patients had died and 87 (10%) had progressed to AML. Figure 1 shows the survival overall and by IPSS risk. Of these patients, 50% did not receive any therapy, 38% had received only transfusions, 37% growth factors and 17% other therapies (thalidomide, hypomethylating agents).
Characteristics associated with overall survival
Associations between unadjusted patient and disease characteristics with survival are shown in Table 2 . Older age, male gender, poor performance status, anemia, thrombocytopenia, leukopenia or leukocytosis, hepatomegaly, IPSS intermediate-1 (versus low), unfavorable risk cytogenetics (all the abnormalities except for diploid and 5q only), number of cytopenias, higher percent of marrow blasts, higher creatinine, lower albumin and Abbreviations: AHD, antecedent hematological disorder; MDAH, MD Anderson Cancer Center; WBC, white blood cell count. Cytopenia defined as hemoglobin less than 10, platelets less than 100 k and absolute neutrophil count of less than 1.5.
infection at referral were significantly associated with a worse survival. A majority of patients (N ¼ 555, 65%) had diploid cytogenetics. No cytogenetic subset accounted for more than 10% of patients (see Table 1 ). After examining different survival outcomes in relation to each cytogenetic subset, we grouped diploid and 5q as favorable cytogenetic characteristics and all others as unfavorable. Only 18 patients had three or more cytogenetic abnormalities: 5 of them had chromosome 5 abnormalities; 6 had chromosome 7 abnormalities; 4 had chromosome þ 8 abnormalities and 3 had miscellaneous chromosome abnormalities. Due to the small number of each subgroup, we did not evaluate the prognostic effect by number of cytogenetic abnormalities.
We then applied a multivariate Cox regression analysis with stepwise backward selection. Initially, all these significant factors were included in the model. Factors that showed no or only limited statistical significant association (P40.01) with survival adjusted for the remaining factors in the model were subsequently deleted from the model. Of note, year of referral had no effect on survival. The final model included age, unfavorable cytogenetics, platelet count (log), hemoglobin and percent of marrow blasts. The Cox regression derived prognostic risk could be calculated as: 0.192 Â (unfavorable cytogenetic; no ¼ 0, yes ¼ 1) þ 0.029 Â (age in years)À0.108 Â (hemoglobin; g per 100 ml)À0.316 log (platelets less than 50 Â 10 6 per l) þ 0.08 Â (percent marrow blasts).
The median score was 0.554 (range À1.4 to 1.9). We observed a gradual decline in survival with increasing score. For clinical practice purposes, a modified model based on bestfitted model was developed by replacing continuous factors with optimal cut points. The modified Cox model with weighted score for each factor is listed in Table 3 . The survival outcome for each score point is listed in Table 4 . Based on this, patients could be divided into three subgroups. Patients with category 1 (n ¼ 182, 21%; score 0-2 points) had a median survival of 80.3 months (95% CI 68-NA) and a 4-year survival rate of 65% (95% CI 55-76). Patients in category 2 (score 3 or 4 points; n ¼ 408, 48%) had a median survival of 26.6 months (95% CI 22-32), and a 4-year survival rate of 33% (95% CI 27-40). Patients in category 3 (score 5-7 points; n ¼ 265, 31%) had a median survival of 14.2 months (95% CI 13-18), and a 4-year survival rate of 7% (95% CI 3-14; Figure 2 ). The proposed model was able to further stratify patients in either IPSS low or intermediate-1 into three risks groups (Po0.0001 for both low-risk and intermediate-1; Figures 3 and 4) . The reverse was not true.
The IPSS scoring did not segregate patients with low or intermediate-1 risk within each of the three risk categories identified by this analysis (data not shown).
Two other factors were studied but not included in the multivariate analysis: ferritin and b2-microglobulin. They were not included in the model because data was available only in a fraction of the patients (Table 1 ). Patients with a ferritin level of more than 1000 ng ml À1 (P ¼ 0.01) ( Figure 5 ) or a b2-microglobulin level of more than 2 mg l À1 (Po0.01; Figure 6 ) had a worse prognosis than those who did not by univariate analysis.
Characteristics associated with AML-free survival
Only 10% of patients eventually transformed to AML. By univariate analysis, IPSS intermediate-1 versus low risk (P ¼ 0.005) increased percentage of marrow blasts (Po0.001), infection at presentation (P ¼ 0.001), and chromosome 7 abnormalities (P ¼ 0.01) were associated with a significant higher risk of AML progression. Only higher percentage of marrow blasts, chromosome 7 anomalies and infection at referral remained in the final multivariate model and were associated with an increased risk of AML transformation (P ¼ 0.01 for all three of them).
Discussion
We describe a new scoring system for patients with lower risk MDS, which computes the presence of poor cytogenetics, age, hemoglobin, platelets and percent of marrow blasts. Based on this, a scoring system was developed which divided patients into three risk categories: category 1 (n ¼ 182, 21%; score 0-2 points) with a median survival of 80.3 months (95% CI 68-NA) and a 4-year survival of 65% (95% CI 55-76); category 2 (score 3 or 4 points; n ¼ 408, 48%) with a median survival of 26.6 months (95% CI 22-32) and a 4-year survival of 33% (95% CI 27-40) and category 3 (score 5-7 points) (n ¼ 265, 31%) with a median survival of 14.2 months (95% CI 13-18) and a 4-year survival of 7% (95% CI [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . These results are of importance for clinical trial development for patients with lower risk MDS and may eventually affect our current MDS practice. At present, many clinicians do not routinely treat patients with lower risk disease, in particular those with low-risk IPSS, until there is evidence of disease progression (increased percentage of marrow blasts or progressive pancytopenia, transfusion needs). This is based on data that patients with lower risk disease have an estimated survival of 2.4-11.8 years based on their age. 3 Our model indicates that patients with lower risk disease can be divided into different prognostic subsets, and that a significant fraction of patients (80%), those in categories 2 and 3, have a Table 3 Multivariate analysis parameters and assigned score Experience with decitabine is restricted to patients with intermediate-1 risk or higher. 6, 10 In that setting, response rates to therapy were similar in all three IPSS subgroups studied. 6, 10 Combination of growth factors improve transfusion needs quality of life, and may potentially improve survival in a subset of patients with lower risk disease. 11, 12 The outcome of patients with lower risk MDS is not improved by the early introduction of allogeneic stem cell transplantation, a modality currently recommended at the time of disease progression. 13 This is due in part to an imbalance regarding early transplant-related mortality and the predicted survival without intervention. The identification of a subset of patients with lower risk disease and poor prognosis may therefore allow the identification of a subset of patients who could be candidates for clinical trials. These investigational studies could include the use of current approved interventions (earlier introduction of therapies such as 5-azacitidine, decitabine) or allow the consideration of use of allogeneic stem cell transplantation in patients with lower risk for whom this intervention is usually delayed, as well as other investigational approaches.
In this study, there was limited but important information regarding the value of ferritin and b2-microglubin. Because of the limited number of patients in whom these data were available, we could not incorporate them in the prognostic score. That said, both parameters had important prognostic implications. In our series of 95 patients with available ferritin levels, those with a ferritin level of more than 1000 ng ml À1 had a significantly worse prognosis (median survival not reached for patients with a ferritin level below 1000 ng ml À1 and 19.8 months for those above, P ¼ 0.007). This is in accordance with the data from Malcovatti et al.
14 and further confirms the importance of iron accumulation in the pathogenesis of MDS, and the need to prospectively evaluate the role of iron chelation in MDS. b2-Microglobulin was also associated with a poor prognosis, an observation previously reported. 15 Of note, CMML morphology in these patients with lower risk disease was not associated with worse prognosis, indicating a difference between this group of patients with lower risk CMML and those with more proliferative higher risk disease. There are several limitations to this study. The first one is that we could not control for the time to referral to our institution (that is, time from MDS diagnosis to referral). Therefore, the survival data presented here is probably shorter than one in which the same analysis was performed from initial presentation. This phenomenon cannot be controlled in most circumstances at referral centers, and probably is also difficult to control time of initial identification of cytopenia to referral to a hematologist. Therefore, this 'time lag' should not affect the conclusion of our results. It is also possible that the population of patients referred were selected because of more complicated clinical features. Second, there is no information regarding the utility of this score to predict response to therapy, nor do we have data on the impact of prior therapy on the model. We are now testing this concept in several prospective clinical trials for patients with lower risk disease. Third and most important is the need of a validation group to confirm these results. Validation of this model in an alternative patient population is fundamental to confirm these results. Until these results are validated, the main use of this model at our center will be to assign patients with poor prognosis to investigational clinical trials.
In summary, we describe a new prognostic score specific for patients with lower risk MDS. The implementation of this model may have significant implications for clinical trial design and eventually treatment decision for patients with lower risk MDS.
